Cognition publishes evidence that treatment with CT1812 improves disease-related biology in patients with Alzheimer’s disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
sigma 2 receptor
Cognition publishes findings identifying sigma-2 (σ-2) receptor as integral in Parkinson’s disease pathology
PITTSBURGH, Oct. 24, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Third International Symposium on Sigma-2 Receptors: Role in Health and Disease. The Symposium will be held in San Diego, California on November 3, 2018 beginning …